These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 5706294)
1. [Treatment of hyperlipemia and steatosis by high doses of meso-insitol hexanicotinate]. Neuman M; Cachin M; Galian P; Charbonnier A; Pergola F Sem Ther; 1968 Dec; 44(10):660-3. PubMed ID: 5706294 [No Abstract] [Full Text] [Related]
2. [Control of hyperlipemia and fatty liver degeneration with tetranicotylfructose]. Zeller W Praxis; 1966 Nov; 55(44):1273-6. PubMed ID: 6013613 [No Abstract] [Full Text] [Related]
3. [New drug combination for medical management of hyperlipemia: clinical study]. Fischer M; Falkensammer C Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):585-9. PubMed ID: 340391 [TBL] [Abstract][Full Text] [Related]
4. [Clinical considerations and functional data on the use of the association of kallikrein and meso-inositol hexanicotinate in the therapy of obliterating arteriopathy]. Blasi A; Licciardello M Clin Ter; 1966 Jul; 38(2):121-58. PubMed ID: 5990194 [No Abstract] [Full Text] [Related]
5. [Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial]. Ziliotto GR; Lamberti G; Wagner A; Cima L; Genco G Arch Sci Med (Torino); 1977; 134(4):359-94. PubMed ID: 345998 [TBL] [Abstract][Full Text] [Related]
6. [Research on skin temperature and internal temperature in subjects with obliterating arteriopathy. Action of the association of kallikrein and meso-inositol hexanicotinate]. Blasi A; Licciardello M Clin Ter; 1966 Oct; 39(1):33-8. PubMed ID: 5998855 [No Abstract] [Full Text] [Related]
7. [The management of hyperlipoproteinemia with Liproreduct]. Fenster R Ther Ggw; 1974 May; 113(5):813-24. PubMed ID: 4603893 [No Abstract] [Full Text] [Related]
8. [Progress on a new form of treatment of lipoarteriosis]. Vargas LE; Velasco JR Rev Esp Cardiol; 1972; 25(3):239-46. PubMed ID: 5069029 [No Abstract] [Full Text] [Related]
9. [Effect of hexanicotinate of meso-inositol in patients with primary hyperlipidemia (author's transl)]. Agusti R; Jordán C; Aste H; Tapia F Rev Invest Clin; 1978; 30(4):327-35. PubMed ID: 362498 [No Abstract] [Full Text] [Related]
10. [Inositol hexanicotinate and its cholesteropenic effect]. Crotte Zamora A; Romo López O Prensa Med Mex; 1974; 39(5-6):287-93. PubMed ID: 4612506 [No Abstract] [Full Text] [Related]
11. [The association of kallikrein and inositol hexanicotinate in the therapy of peripheral obliterating arteriopathy]. D'Ayala Valva G Recenti Prog Med; 1966 Jun; 40(6):XIX-XXXVI. PubMed ID: 6014405 [No Abstract] [Full Text] [Related]
12. [The effect of a lipid-reducing clofibrate-inositolnicotinate combination compared to clofibrate. A double-blind study]. Schäfer B; Kluthe R Med Welt; 1975 Apr; 26(14):655-63. PubMed ID: 1099394 [No Abstract] [Full Text] [Related]
13. [The problem of type changes in hyperlipoproteinemia (type IIb, IV, V) under clofibrate and m-inositol nicotinate therapy]. Schwartzkopff W; Zschiedrich M Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():825-9. PubMed ID: 196436 [No Abstract] [Full Text] [Related]
14. [Clinical study with a new antihyperlipemic combination]. Pistautz H Arzneimittelforschung; 1977; 27(1):152-6. PubMed ID: 576816 [TBL] [Abstract][Full Text] [Related]